alpha-glucosidase inhibitors

alpha-glucosidase inhibitors

Drugs used to treat Type II (non-insulin-dependent) DIABETES. An example is acarbose (Glucobay).
References in periodicals archive ?
By drug class, the global diabetes drug market has been segmented into insulin, sensitizers, alpha-glucosidase inhibitors, SGLT-2 inhibitors, secretagogues, peptide analogs, and others.
Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis.
Alpha-glucosidase inhibitors (including acarbose and miglitol) delay breakdown of carbohydrates in the small intestine, and lower postprandial glucose and insulin levels.
Several intervention studies have demonstrated that onset of diabetes can be prevented or delayed with intensive lifestyle modification and oral antidiabetic agents including metformin, thiazolidinediones and alpha-glucosidase inhibitors. Prediabetes management should focus on lifestyle modification and multiple risk factor management.
Voglibose (Basen, AO-128), one of the most important alpha-glucosidase inhibitors. Curr.
In patients with type 1 diabetes, insulin is used, whereas in patients with type 2 diabetes, sulfonylurea, biguanides, meglitinides, dipeptidyl-peptidase-4 (DPP-4) inhibitors, alpha-glucosidase inhibitors, sodium glucose cotransporter 2 inhibitors (SGLT2), and glucagon-like peptide-1 (GLP-1) agonist are used.
* Alpha-glucosidase inhibitors (AGIs), such as acarbose (Precose) and miglitol (Glyset), block the absorption of ingested carbohydrates in the small intestine.
There are seven pharmacologic subclasses of oral antidiabetic agents: alpha-glucosidase inhibitors, biguanides, dipeptidyl peptidase-4 inhibitors, meglitinides, sulfonylureas, sodium-glucose cotransporter-2 inhibitors, and thiazolidinediones.
The greatest compliance was observed with alpha-glucosidase inhibitors (100%) and meglitinides (100%); nonetheless, only 5 participants used these drugs.
Alternative Agents in Type 1 Diabetes in Addition to Insulin Therapy Metformin, Alpha-Glucosidase Inhibitors, Pioglitazone, GLP-1 Agonists, DPP-IV Inhibitors, and SGLT-2 Inhibitors.
Schnell, "Alpha-glucosidase inhibitors 2012--cardiovascular considerations and trial evaluation," Diabetes and Vascular Disease Research, vol.